• Fortrea enters into a definitive agreement to acquire the Early Phase Services division of Worldwide Clinical Trials
  • Includes a 60,000 sq. ft. GLP bioanalytical lab in Austin; a 200-bed GCP-compliant clinical pharmacology unit in San Antonio; and a biospecimen storage facility in Pflugerville, Texas
  • Enables integrated execution of early-phase studies with large and small molecule bioanalytical capabilities, enhancing Fortrea’s ability to deliver faster, more integrated early clinical development solutions for simple and complex clinical studies
  • Strengthens Fortrea’s end-to-end clinical development platform, supporting customers from first-in-human studies through Phase IV and post-approval evidence generation
  • Supports Fortrea’s growth strategy through expanded scientific capabilities, increased early clinical development capacity and enhanced ability to create long-term value for shareholders
  • Supports Worldwide Clinical Trials’ existing rapid global growth across oncology, neuroscience, internal medicine, and rare disease
  • Provides continuity of operations, study delivery and customer support throughout the transition through a strategic alliance agreement between the companies